Clinical trial
Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage…
NCT00003339 · University of Southern California, Other · Completed
Key facts
| NCT number | NCT00003339 |
|---|---|
| Title | Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma |
| Official title | A Randomized Phase II Trial of a Vaccine Combining Tyrosinase/gp100 Peptides Emulsified With Montanide ISA 51 With and Without Interleukin-12 for Patients With Resected Stages III and IV Melanoma |
| Lead sponsor | University of Southern California, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Intraocular Melanoma, Melanoma (Skin) |
| Intervention type | Biological |
| Interventions | gp100 antigen, incomplete Freund's adjuvant, recombinant interleukin-12, tyrosinase peptide |
| Enrollment | 48 |
| Start date | Nov 1, 1998 |
| Primary completion | Nov 1, 1999 |
| Completion | Sep 1, 2004 |
| First posted | Sep 13, 2004 |
| Last update posted | May 22, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: